The emerging role of FTY720 (Fingolimod) in cancer treatment

White, Christopher, Alshaker, Heba, Cooper, Colin, Winkler, Matthias and Pchejetski, Dmitri (2016) The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget, 7 (17). pp. 23106-23127. ISSN 1949-2553

[img]
Preview
PDF (Published manuscript) - Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

FTY720 (Fingolimod) is a clinically approved immunomodulating therapy for multiple sclerosis that sequesters T-cells to lymph nodes through functional antagonism of sphingosine-1-phosphate 1 receptor. FTY720 also demonstrates a proven efficacy in multiple in vitro and in vivo cancer models, suggesting a potential therapeutic role in cancer patients. A potential anticancer mechanism of FTY720 is through the inhibition of sphingosine kinase 1, a proto-oncogene with in vitro and clinical cancer association. In addition, FTY720's anticancer properties may be attributable to actions on several other molecular targets. This study focuses on reviewing the emerging evidence regarding the anticancer properties and molecular targets of FTY720. While the clinical transition of FTY720 is currently limited by its immune suppression effects, studies aiming at FTY720 delivery and release together with identifying its key synergetic combinations and relevant patient subsets may lead to its rapid introduction into the clinic.

Item Type: Article
Additional Information: All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
Uncontrolled Keywords: sphingolipid ,sphingosine kinase,fingolimod,fty720,cancer
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Related URLs:
Depositing User: Pure Connector
Date Deposited: 27 May 2016 10:00
Last Modified: 10 Nov 2020 00:51
URI: https://ueaeprints.uea.ac.uk/id/eprint/59103
DOI: 10.18632/oncotarget.7145

Actions (login required)

View Item View Item